Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a
pressing need for tools to facilitate remote visits and monitoring. Digital health technology …

Importance Sprifermin is under investigation as a disease-modifying osteoarthritis drug.
Objective To evaluate the effects of sprifermin on changes in total femorotibial joint cartilage …

Introduction Patients with IgA nephropathy (IgAN) and persistent proteinuria are at risk of
progression to kidney failure. Atacicept is a novel B-cell–targeted immunomodulator, shown …

A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of
intra-articular rhFGF18 (sprifermin) in Page 1 Clinical and Experimental Rheumatology 2016; 34 …

Objectives In the phase II FGF-18 Osteoarthritis Randomized Trial with Administration of
Repeated Doses (FORWARD) study, sprifermin demonstrated cartilage modification in the …

Objective To determine whether an anabolic drug (sprifermin) is capable of reducing
cartilage loss wherever it occurs in a given knee, using a subject‐specific, location …

Background A recent publication on efficacy of Sprifermin for knee osteoarthritis (OA) using
quantitatively MRI-defined central medial tibio-femoral compartment cartilage thickness as …

Objectives Atacicept reduced SLE disease activity in the phase 2b ADDRESS II study,
particularly in patients with high disease activity (HDA; SLEDAI-2K≥ 10) at screening. We …

Background: CLASSIC-MS evaluated the long-term efficacy of cladribine tablets in patients
with relapsing multiple sclerosis. Objective: Report long-term mobility and disability beyond …

Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ
systems. Many investigational agents have failed or shown only modest effects when added …